How GLP-1s, Wegovy, Zepbound are reshaping the economy

Miracle medications, obesity treatments and slim Jabs. Call them what you want, and a few medications have been a more transformational effect on Wall Street and waist lines over the last decades of the GLP-1S.

Familiarly known under the names of the wegovy and zepbound brands, peptide -1 alarms (GLP -1) similar to glucagon is a category of medications used to treat type 2 diabetes and obesity by simulating hormones produced in the intestine to suppress a person’s appetite and regulate blood sugar.

Since wegovy got our first approval to treat obesity in 2021, and Zepbound in 2023, medicines rose to fame, brought long solutions to tens of millions of patients and operate the growth of parental companies Novo Nordsk and Eli Lily.

Obesity is a great risk factor in many major causes of death. With the emergence of new applications – and competitors – for medicines, Wall Street is betting on a large industry, with estimates indicating that it may be useful More than $ 100 billion By 2030.

Sophie Dicks, head of medical affairs at MEDEXPress, said that the applications of the possible narration of medicines were “promising unexpected”, with new indicators on psoriasis, asthma, chronic kidney disease, fatty liver diseases, obstruction sleeping, and cold disease.

Experts say that large -scale spaces of applications can open possible effects on both health results and economics.

The current cost of drugs is large, as the US list prices range for a month from Wegbound from Lily’s Zepbound or Novo from $ 1,079.77 to $ 1,349.02. Estimates provided by the JAMA Health Forum indicate that the American medical care coverage will increase the net spending under the Retary Health Program program By 47.7 billion dollars On the next ten years.

But the expected health and economic results are also important. Weak health of obesity and obesity associated with diseases that are highly associated with comprehensive health and productivity systems, including during the lost hours, early death and informal care provider.

Goldman Sachs estimate that GLP-1S can enhance US GDP (GDP) by 0.4 % by increasing productivity and health deaths, assuming the adoption of the foundation line of 30 million users, according to the 2024 report. 2 % of adults -Nearly 5 million people-they were taking GLP-1S as of the Nagal Health Health report.

“Weak health imposes significant economic costs that will diminish if health results improved,” said Goldman Sachs analysts in the report. “Academic studies find that individuals with obese are less likely to work … and less productive when they do.”

Meanwhile, in Denmark, the market value made by Wegovy Novo Nordisk was crashed into the gross domestic product in its homeland in 2024, and the large and increasing industry in the country is still in its country. A big contribution For the economy.

In this way, the perceived capabilities of the GLP-1S are seen-whether to treat obesity and diabetes as well as other health conditions-which raises a new era of drug innovation, as DIX describes the potential effect as “deep” for both future drugs developing and creating new job opportunities.

Pharma’s giants, including Astrazenecaand Vizarand Rush and Zealand Pharma It is already developing competitive obesity treatments, while many of them are expanding in metabolic and heart disease, and developing obesity as an entry point.

“It is also important to keep in mind that the first in its class is rarely the best in its class. Follow -up medications may be more powerful and more selective, with side effects or controlling them with mixed treatments. As a result, I expect that there will be improvements in the event, endurance (lower side effects),” said Dixes.

This can have significant effects on fast -moving consumer commodity companies (FMCG), as well as food producers on a larger scale. In fact, some companies are like Nestle and Danone It has already started launching new lines to diversify the base of its products and meet the needs of trends. These include high protein meals, sizes of smaller foods and foods that aim to encourage muscles.

“Manufacturers and retailers have very specific customers who buy very specific products,” said Yansen. He pointed out that this is a good thing to build the brand loyalty. “But when you have something that changes the behavior of consumers, it can also be done by weight loss, this becomes risky.”

The effect of medications can also exceed food. GLP-1S Control Control by Targeting the course of the brain rewardSpecifically, dopamine release a portion of the brain associated with stimulation, pleasure and reward. As such, early studies indicate drug applications in addiction treatment.

“Dicks extend the bonus system modification beyond food, with early evidence indicating benefits in reducing the use of alcohol, drug adoption, and even gambling,” Dix said.

This has raised concerns about the producers of recreational steroids such as alcohol and tobacco. The Cornell study, for its part, noticed any “meaningful” change in alcohol purchases between the GLP-1 users, reflecting other literature indicating a possible decrease in the severity of drinking rings instead of hesitation.

Giant Spirits and Johnny Walker Diago He said earlier this month that he was “closely monitoring” on the GLP-1, but he pointed out that the influence so far was “not great.”

Elsewhere, the repercussions of other sectors appear widely. Analysts have assumed retail transformations-including sales of the largest active clothes to reduce the huge demand-and provide fuel to airlines of lighter passengers. Sports halls and personal trainers can also see a rise in demand, while holiday resorts benefit from new opportunities to meet the needs of the most active and directed visitors to health.

More immediately, restaurants are calculated from fast food chains to high -end restaurants with a new scene for consumers and low future demand.

“In the short term, yes, these drugs reduce spending in rapid restaurants and fast service. At the national level, this is already translated into billions of dollars from low sales,” said Luokonite.

“But the long-term image is much less confident. The final effect depends greatly on whether people are constantly staying on the time of time-and we simply do not know that yet.”

Drug makers have already gone to some extent LowerWith this trend, it is scheduled to continue amid policy changes, including the pricing of drugs in the United States, Donald Trump, and increase competition in the market. However, with the prolonged use of drugs that are assigned to the general and personal strings, analysts warn that policy makers should be aware of the exacerbation of social and economic divisions.

“If the wealthy gets a pharmacist who makes them thin, then the independence is already in weight – which is already associated with income and education – increases its condensation.”

“This is certainly something that will have a negative impact on the wider society,” he added.